Biofidelity

Biofidelity is a private, commercial-stage diagnostics company addressing critical gaps in cancer genomic testing. Its proprietary technology platform underpins two main product lines: the Aspyre® Clinical Test (a Laboratory Developed Test for NSCLC) and Enspyre®, forming an end-to-end solution from early detection to treatment monitoring. The company's assays are distinguished by their simplicity, speed (2-day turnaround), and ability to work with challenging samples, positioning it to capture share in the rapidly growing precision oncology market. Biofidelity operates a CAP-accredited, CLIA-certified lab in the US and sells reagents for research use.

Proprietary molecular platform enabling simultaneous DNA and RNA analysis from a single assay (tissue or blood) for sensitive, specific, and rapid detection of cancer biomarkers.

Biofidelity competes in the comprehensive genomic profiling space against large-cap players like Foundation Medicine (Roche) and Guardant Health, as well as NGS platform companies like Illumina and Thermo Fisher. Its differentiation is based on assay simplicity, rapid turnaround, and combined DNA/RNA analysis from a single test, targeting workflow inefficiencies in current standard-of-care.